Published in Cancer Weekly, February 8th, 2005
On September 24, 2004, the U.S. Food and Drug Administration (FDA) approved Palladone Capsules for the management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time (weeks to months) or longer. The pain may arise from either cancer or non-cancer conditions.
While long-acting (q12h) hydromorphone formulations are available in Canada, the United Kingdom, and Germany, Palladone is the first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.